Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Association of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19-Related Outcome
24 Pages Posted: 14 Apr 2020
More...Abstract
Background: Different hypotheses suggest a contradictory association of angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors with potential adverse or favorable effects in patients infected with SARS-CoV-2. This study aimed to clarify if the use of ARB and/or ACE inhibitor should be continued in COVID-19 patients with comorbidities.
Methods: Data related to 8,266 patients with laboratory-confirmed SARS-CoV-2 infection through March 16, 2020, were retrieved. We evaluated the association of ARBs and ACE inhibitors on SARS-CoV-2-related mortality within 60 days. Furthermore, a comparison of hazard ratio (HR) was performed between SARS-CoV-2 infected patients and a retrospective cohort of patients hospitalized with pneumonia between January and June 2019 in Korea.
Findings: The median age of the patients infected by SARS-CoV-2 was 45 years, with 61.52% being female. Prevalence of hypertension was 19.04%, and ARBs and ACE inhibitors were prescribed in 11.38% and 0.44% of overall patients, respectively. As of March 24, 2020, 112 patients (1.42%) succumbed to death. The crude HR of hypertension was 4.13 (95% confidence interval [CI]. 2.48 – 6.62, p < 0.0001). However, after adjusting age, sex, and comorbidities, the association of hypertension and death was not significant (HR 1.254, 95% CI 0.734 – 2.144, P = 0.4080). Cox regression showed no increase in HR associated with ARB + ACE inhibitor groups (HR 1.067, 95% CI 0.676 – 1.650) after adjusting for age, sex, and comorbidities. SARS-CoV-2 infected patients showed a trend similar to that of the retrospective pneumonia cohort.
Interpretation: Results of the present study indicate no adverse outcome of COVID-19 in patients prescribed with ARBs or ACE inhibitors. These results support the sustained use of ARBs and ACE inhibitors in SARS-CoV-2 infection.
Funding Statement: Research Grant from the Korea Centers for Disease Control and Prevention (#4838- 330-320-01) and Seoul National University Hospital (#04-2020-0030).
Declaration of Interests: The authors declare no competing interests.
Ethics Approval Statement: The study was approved by the Institutional Review Board of Seoul National University Hospital (No. 2003- 102-1109). Informed consent was waived, both, in the light of the urgent need to collect data, and because the study was based on routinely collected administrative or claims data.
Keywords: COVID-19; Hypertension; Angiotensin receptor blocker
Suggested Citation: Suggested Citation